Flag Ship Acquisition (ETHZ) Stock Price, News & Analysis

Company Overview

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $2.65 to $2.90
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 11.34 million shs
• Average Volume: 28.00 million shs
• Market Capitalization: $16.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ETHZ Stock Analysis - Frequently Asked Questions

How have ETHZ shares performed this year?

Flag Ship Acquisition's stock was trading at $2.81 at the start of the year. Since then, ETHZ stock has increased by 0.0% and is now trading at $2.81.

How do I buy shares of Flag Ship Acquisition?

Shares of ETHZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ETHZ
• CIK: 1690080
• Web: N/A
• Phone: (650) 507-0669
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($15.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -141.25%
• Return on Assets: -80.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.58
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.91 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 6,040,000
• Free Float: 3,732,000
• Market Cap: $16.97 million
• Optionable: N/A
• Beta: 0.37